Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban thromboprophylaxis during neoadjuvant therapy for muscle-invasive bladder cancer (ACB)
2024-518861-90-00Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised trial of apixaban in muscle-invasive bladder cancer (MIBC) and venous thromboembolism (VTE) (2 arms), sponsored by Helsinki University Hospital. Primary endpoints: Primary efficacy outcome and Primary safety outcome. Planned start Jul 2026; status: authorised.
02
Drugs
apixaban
03
Conditions
muscle-invasive bladder cancer (MIBC)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2024-518861-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518861-90-00.